By Colin Kellaher
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder.
The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter.
Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses.
Shares of Supernus were recently up 5.5% to $39.42.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 04, 2025 10:10 ET (15:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。